Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Ignite Creation Date:
2025-12-24 @ 11:44 PM
Ignite Modification Date:
2025-12-25 @ 9:37 PM
NCT ID:
NCT01817751
Description:
Number of patients with adverse events, and types of events, as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0).
Frequency Threshold:
0
Time Frame:
From initiation of study therapy to completion of adverse event (AE) observation period, up to 30 days following the end of study treatment up to 7 years.
Study:
NCT01817751
Study Brief:
Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
Event Groups(If Any):
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Treatment (Sorafenib Tosylate, Valproic Acid, Sildenafil) | * Sorafenib 400 mg orally twice a day; * Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day; * Sildenafil 50 mg orally twice a day A cycle consists of 4 weeks. \*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol) sorafenib tosylate: Given by mouth valproic acid: Given by mouth sildenafil citrate: Given by mouth | 1 | None | 17 | 47 | 47 | 47 | View |
Serious Events(If Any):
Serious Events
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| hyponatremia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hypophosphatemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| urinary incontinence | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v4.0 | View |
| Anemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v4.0 | View |
| Abdominal Distension | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| abdominal Pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| Colonic Perforation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| ileal fistula | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| pancreatitis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| edema Limbs | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | NCI CTCAE v4.0 | View |
| Fatigue | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| gait disturbance | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| general disorders and administration site conditions | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| multi-organ failure | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| appendicitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v4.0 | View |
| fall | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | NCI CTCAE v4.0 | View |
| fracture | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | NCI CTCAE v4.0 | View |
| alanine aminotransferase increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| aspartate aminotransferase increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| investigations-other, specify | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| lipase increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| neutrophil count decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| Platelet count decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| White blood cell decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| Alkalosis | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| dehydration | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hyperglycemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hypokalemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| generalized muscle weakness | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| muscle weakness, right-sided | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | NCI CTCAE v4.0 | View |
| concentration impairment | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| dysphasia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| hypersomnia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| lethargy | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| seizure | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| somnolence | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| confusion | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v4.0 | View |
| hematuria | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v4.0 | View |
| renal calculi | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v4.0 | View |
| hypoxia | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v4.0 | View |
| social circumstances-other, specify | SYSTEMATIC_ASSESSMENT | Social circumstances | NCI CTCAE v4.0 | View |
| hematoma | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v4.0 | View |
| hypotension | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v4.0 | View |
| thromboembolic event | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v4.0 | View |
Other Events(If Any):
Other Events
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| anemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | NCI CTCAE v4.0 | View |
| atrial fibrillation | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v4.0 | View |
| cardiac disorders-other, specify | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v4.0 | View |
| flatulence | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| gastroesophageal reflux disease | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| Gastrointestinal disorders - Other, specify | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| Gastrointestinal pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| sinus bradycardia | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v4.0 | View |
| sinus tachycardia | SYSTEMATIC_ASSESSMENT | Cardiac disorders | NCI CTCAE v4.0 | View |
| ear and labyrinth disorders-other, specify | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | NCI CTCAE v4.0 | View |
| hearing impaired | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | NCI CTCAE v4.0 | View |
| tinnitus | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | NCI CTCAE v4.0 | View |
| vertigo | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | NCI CTCAE v4.0 | View |
| cushingoid | SYSTEMATIC_ASSESSMENT | Endocrine disorders | NCI CTCAE v4.0 | View |
| endocrine disorders-other, specify | SYSTEMATIC_ASSESSMENT | Endocrine disorders | NCI CTCAE v4.0 | View |
| hyperthyroidism | SYSTEMATIC_ASSESSMENT | Endocrine disorders | NCI CTCAE v4.0 | View |
| blurred vision | SYSTEMATIC_ASSESSMENT | Eye disorders | NCI CTCAE v4.0 | View |
| eye disorders-other, specify | SYSTEMATIC_ASSESSMENT | Eye disorders | NCI CTCAE v4.0 | View |
| eye pain | SYSTEMATIC_ASSESSMENT | Eye disorders | NCI CTCAE v4.0 | View |
| watering eyes | SYSTEMATIC_ASSESSMENT | Eye disorders | NCI CTCAE v4.0 | View |
| abdominal distension | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| abdominal pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| bloating | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| constipation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| diarrhea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| dry mouth | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| dyspepsia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| dysphagia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| fecal incontinence | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| Hemorrhoidal hemorrhage | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| mucositis oral | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| oral dysesthesia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| oral hemorrhage | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| toothache | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| edema face | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| edema limbs | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| fatigue | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| fever | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| gait disturbance | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | NCI CTCAE v4.0 | View |
| General disorders and administration site conditions - Other, specify | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| Generalized edema | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| irritability | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| malaise | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| non-cardiac chest pain | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| pain | SYSTEMATIC_ASSESSMENT | General disorders | NCI CTCAE v4.0 | View |
| allergic reaction | SYSTEMATIC_ASSESSMENT | Immune system disorders | NCI CTCAE v4.0 | View |
| eye infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v4.0 | View |
| infections and infestations-other, specify | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v4.0 | View |
| mucosal infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v4.0 | View |
| nail infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v4.0 | View |
| otitis media | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v4.0 | View |
| papulopustular rash | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v4.0 | View |
| pharyngitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v4.0 | View |
| prostate infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v4.0 | View |
| skin infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v4.0 | View |
| soft tissue infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v4.0 | View |
| urinary tract infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | NCI CTCAE v4.0 | View |
| bruising | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | NCI CTCAE v4.0 | View |
| wound complication | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | NCI CTCAE v4.0 | View |
| wound dehiscence | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | NCI CTCAE v4.0 | View |
| Activated partial thromboplastin time prolonged | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| Alanine aminotransferase increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| alkaline phosphatase increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| aspartate aminotransferase increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| blood bilirubin increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| cholesterol high | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| creatinine increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| GGT increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| hemoglobin increased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| investigations - other, specify | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| lymphocyte count decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| neutrophil count decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| platelet count decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| weight gain | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| weight loss | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| white blood cell decreased | SYSTEMATIC_ASSESSMENT | Investigations | NCI CTCAE v4.0 | View |
| anorexia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| dehydration | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| glucose intolerance | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hyperglycemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hyperkalemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hypermagnesemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hypernatremia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hypertriglyceridemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hypoalbuminemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hypocalcemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hypoglycemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hypokalemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| Hypomagnesemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hyponatremia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| hypophosphatemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| Metabolism and nutrition disorders - Other, specify | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | NCI CTCAE v4.0 | View |
| arthralgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| back pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| buttock pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| chest wall pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| generalized muscle weakness | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| joint range of motion decreased | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| muscle weakness left-sided | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| muscle weakness lower limb | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| muscle weakness right-sided | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| muscle weakness upper limb | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| Musculoskeletal and connective tissue disorder - Other, specify | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| myalgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| pain in extremity | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | NCI CTCAE v4.0 | View |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | NCI CTCAE v4.0 | View |
| cognitive disturbance | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| concentration impairment | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| depressed level of consciousness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| dizziness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| dysarthria | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| dysesthesia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| dysgeusia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| dysphasia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| edema cerebral | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| encephalopathy | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| facial muscle weakness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| hypersomnia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| intracranial hemorrhage | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| ischemia cerebrovascular | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| lethargy | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| memory impairment | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| nervous system disorders- other, specify | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| paresthesia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| peripheral sensory neuropathy | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| presyncope | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| seizure | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| sinus pain | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| somnolence | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| spasticity | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| tremor | SYSTEMATIC_ASSESSMENT | Nervous system disorders | NCI CTCAE v4.0 | View |
| Agitation | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v4.0 | View |
| anxiety | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v4.0 | View |
| confusion | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v4.0 | View |
| delusions | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v4.0 | View |
| depression | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v4.0 | View |
| hallucinations | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v4.0 | View |
| insomnia | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v4.0 | View |
| personality change | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v4.0 | View |
| psychiatric disorders- other, specify | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v4.0 | View |
| suicidal ideation | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | NCI CTCAE v4.0 | View |
| hematuria | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v4.0 | View |
| proteinuria | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v4.0 | View |
| renal calculi | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v4.0 | View |
| urinary frequency | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v4.0 | View |
| urinary incontienence | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v4.0 | View |
| urinary retention | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v4.0 | View |
| urinary tract pain | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v4.0 | View |
| urinary urgency | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | NCI CTCAE v4.0 | View |
| genital edema | SYSTEMATIC_ASSESSMENT | Reproductive system and breast disorders | NCI CTCAE v4.0 | View |
| allergic rhinitis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v4.0 | View |
| atelectasis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v4.0 | View |
| cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v4.0 | View |
| dyspnea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v4.0 | View |
| epistaxis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v4.0 | View |
| hiccups | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v4.0 | View |
| hoarseness | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v4.0 | View |
| nasal congestion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v4.0 | View |
| pleural effusion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v4.0 | View |
| postnasal drip | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v4.0 | View |
| sleep apnea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v4.0 | View |
| sore throat | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | NCI CTCAE v4.0 | View |
| alopecia | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v4.0 | View |
| body odor | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v4.0 | View |
| dry skin | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v4.0 | View |
| pain of skin | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v4.0 | View |
| palmar-plantar erythrodysesthesia syndrome | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v4.0 | View |
| pruritus | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v4.0 | View |
| purpura | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v4.0 | View |
| rash acneiform | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v4.0 | View |
| rash maculo-papular | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v4.0 | View |
| scalp pain | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v4.0 | View |
| skin and subcutaneous tissue disorders- other, specify | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v4.0 | View |
| skin ulceration | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v4.0 | View |
| flushing | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v4.0 | View |
| hematoma | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v4.0 | View |
| hypertension | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v4.0 | View |
| hypotension | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v4.0 | View |
| thromboembolic event | SYSTEMATIC_ASSESSMENT | Vascular disorders | NCI CTCAE v4.0 | View |
| fall | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | NCI CTCAE v4.0 | View |
| fracture | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | NCI CTCAE v4.0 | View |
| injury, poisoning and procedural complications- other, specify | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | NCI CTCAE v4.0 | View |
| Nail Ridging | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | NCI CTCAE v4.0 | View |
| Surgical and medical procedures - Other, specify | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | NCI CTCAE v4.0 | View |